跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

07741

Supelco

依维莫司

analytical standard

别名:

42-O-(2-羟乙基）雷帕霉素

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C53H83NO14
CAS号:
159351-69-6
分子量:
958.22
MDL编号:
MFCD00929329
UNSPSC代码:
41116107
PubChem化学物质编号:
329748511

等级

analytical standard

方案

≥95% (HPLC)

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

储存温度

−20°C

SMILES字符串

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI key

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因信息

human ... FKBP1A(2280)

正在寻找类似产品? 访问 产品对比指南

包装

Bottomless glass bottle. Contents are inside inserted fused cone.

分析说明

精确浓度和有效期请见每个包装内的证书。

法律信息

CERTICAN is a registered trademark of Novartis AG

象形图

Health hazardEnvironment
GHS08,GHS09

警示用语：

Warning

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

靶器官

Kidney,Testes

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCBS2040V
BCBR8517V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

帕博昔利 ≥98% (HPLC)

Sigma-Aldrich

PZ0383

帕博昔利

Inge Verbrugge et al.
Radiation research, 182(2), 219-229 (2014-06-25)
Radiotherapy is a successful treatment modality for localized cancer. Our group has been exploring radiotherapy in combination with immunotherapy (radioimmunotherapy) to enhance systemic antitumor responses. Previously, we have shown that when local radiotherapy was combined with monoclonal antibodies (mAbs) (that
Robert J Motzer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(25), 2765-2772 (2014-07-23)
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma. RECORD-3 used a crossover treatment
Joëlle Elias et al.
Heart (British Cardiac Society), 104(17), 1432-1438 (2018-02-22)
During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine
Alfonso Ielasi et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 89(7), 1129-1138 (2016-10-25)
To assess the feasibility and the clinical results following a prespecified bioresorbable vascular scaffold (Absorb BVS) implantation strategy in ST-elevation myocardial infarction (STEMI) patients. Concerns raised about the BVS safety in STEMI setting because a not negligible thrombosis rate was
Simron Singh et al.
Neuroendocrinology, 106(3), 211-220 (2017-05-30)
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门